Pub. Date : 2018 Jun 22
PMID : 29738763
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Several clinical studies have highlighted ROS1 as a promising therapeutic target because crizotinib, a multi-targeted drug against ROS1, ALK, and the MET proto-oncogene, has elicited remarkable responses in ROS1-rearrangements NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | Several clinical studies have highlighted ROS1 as a promising therapeutic target because crizotinib, a multi-targeted drug against ROS1, ALK, and the MET proto-oncogene, has elicited remarkable responses in ROS1-rearrangements NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 3 | Several clinical studies have highlighted ROS1 as a promising therapeutic target because crizotinib, a multi-targeted drug against ROS1, ALK, and the MET proto-oncogene, has elicited remarkable responses in ROS1-rearrangements NSCLC. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 4 | This eventually enabled us to engraft and stably grow the cells in vivo, and subsequently evaluate various ROS1 inhibitors against HCC78xe3 cells by overexpressing crizotinib-resistant mutations in the ROS1 kinase domain including G2032R and D2033 N. We newly found that lorlatinib, a next generation ROS1/ALK inhibitor, remain the activity against D2033 N mutation. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 5 | This eventually enabled us to engraft and stably grow the cells in vivo, and subsequently evaluate various ROS1 inhibitors against HCC78xe3 cells by overexpressing crizotinib-resistant mutations in the ROS1 kinase domain including G2032R and D2033 N. We newly found that lorlatinib, a next generation ROS1/ALK inhibitor, remain the activity against D2033 N mutation. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 6 | Furthermore, we demonstrated that HCC78xe3 cells expressing SLC34A2-ROS1 G2032R, and D2033 N, but not wild type (WT) cells, were resistant to crizotinib in vivo. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |